Octreotide-Induced Long QT Syndrome in a Child with Congenital Hyperinsulinemia and a Novel Missense Mutation (p.Met115Val) in the ABCC8 Gene

Celik N., CİNAZ P., Emeksiz H. C., Hussain K., Camurdan O., BİDECİ A., ...Daha Fazla

HORMONE RESEARCH IN PAEDIATRICS, cilt.80, sa.4, ss.299-303, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 80 Sayı: 4
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1159/000354666
  • Dergi Adı: HORMONE RESEARCH IN PAEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.299-303
  • Anahtar Kelimeler: Congenital hyperinsulinism, Long QT, Octreotide, ABCC8, SOMATOSTATIN ANALOGS, INDUCED BRADYCARDIA, HEART, MANAGEMENT, MECHANISMS, DIAGNOSIS
  • Gazi Üniversitesi Adresli: Evet

Özet

Background/ Aims: Congenital hyperinsulinism (CHI) denotes an inappropriate secretion of insulin from pancreatic beta-cells in the presence of a low blood glucose level due to various genetic causes. Diazoxide is the first-line medical treatment for CHI. In case of failure, a somatostatin analogue called octreotide is used. A prolonged QT interval is an unusual side effect of octreotide which can be lethal if unrecognized. Case Presentation: We report on a 35-day-old infant who was diagnosed with CHI on the 3rd day of his life and underwent pancreatectomy due to failure of medical treatment at 8 months. His genetic analysis revealed a compound heterozygosity for a novel missense mutation (p.Met115Val) and a nonsense mutation (p.Trp1339X) in the ABCC8 gene. Furthermore, at the 6th month of follow-up, a long QT (0.49 s) was determined by ECG examination, which was normalized following discontinuation of octreotide treatment after pancreatectomy. Thus, the long QT was considered to be secondary to octreotide medication. Conclusion: We recommend ECG monitoring before and during octreotide treatment in order to recognize a prolonged QT interval and to prevent related complications in cases with congenital hyperinsulinemia. (C) 2013 S. Karger AG, Basel